Larimar Soars as FDA Grants Breakthrough Status to First Potential Disease-Modifying FA Drug
Larimar shares jump 31% after FDA grants Breakthrough Therapy Designation to nomlabofusp for Friedreich’s ataxia. Company eyes accelerated approval with BLA filing in June 2026.
